(Q44579906)

4 December 2017

0 references

Salvage treatments in Hodgkin's disease (English)

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90208-U

4 December 2022

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90208-U

4 December 2022

author name string

G. Bonadonna

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1828957

4 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1828957

4 December 2022

publication date

1 January 1991

1 reference

full work available at URL

4 December 2017

https://api.elsevier.com/content/article/PII:027753799190208U?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90208-U

https://api.elsevier.com/content/article/PII:027753799190208U?httpAccept=text/plain

4 December 2022

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90208-U

European Journal of Cancer

4 December 2022

published in

1 reference

4 December 2017

27

1 reference

4 December 2017

5

1 reference

4 December 2017

530-531

1 reference

Influence of clinical trials on current treatment strategy for Hodgkin's disease

4 December 2017

1

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90208-U

Hodgkin's disease in patients over sixty years old

4 December 2022

3

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90208-U

The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin's disease

4 December 2022

4

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90208-U

Stage IIB Hodgkin's disease: the Stanford experience

4 December 2022

5

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90208-U

Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease

4 December 2022

6

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90208-U

Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience

4 December 2022

8

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90208-U

High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease

4 December 2022

9

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90208-U

Treatment of refractory and relapsed Hodgkin's disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support

4 December 2022

10

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90208-U

4 December 2022

Identifiers

1 reference

4 December 2017

1 reference